MJMatthew W. Johnson

Matthew W. Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Recognitions

Top Cited Scholar (2024)

Matthew W. Johnson has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Next-Generation Psychedelic Drug Development

    by Lindsay P. Cameron, Matthew W. Johnson, Kevin S. Murnane, Mark M. Rasenick, Charles D. Nichols

    Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the strengths and limitations of current assays and models. Finally, we provide guidance and considerations for next-generation psychedelic drug development.

  • Open Access

    Development of Japanese Versions of the 4‐Item Mystical Experience Questionnaire and 7‐Item Challenging Experience Questionnaire

    by Futaba Umemura, Hiroko Kotajima‐Murakami, Justin C. Strickland, Albert Garcia‐Romeu, Matthew W. Johnson, Kazutaka Ikeda

    Introduction: Interest in therapeutic applications of psychedelics has recently resurged. Mystical‐type and challenging experiences that are elicited by psychedelics are commonly assessed using the 30‐item Mystical Experience Questionnaire (MEQ‐30) and the 26‐item Challenging Experience Questionnaire (CEQ), respectively. The brief 4‐item MEQ (MEQ‐4) and 7‐item CEQ (CEQ‐7) may reduce respondent burden, but Japanese versions have not yet been developed. This study developed Japanese versions of the MEQ‐4 and CEQ‐7. Methods: In translating the MEQ‐4 and CEQ‐7, our procedures were informed by the recommendations of the “Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient‐Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation.” Separately, experts in psychedelics reviewed semantic nuances and the naturalness and appropriateness of the Japanese wording. Cognitive debriefing was not conducted because recruiting an appropriate Japanese‐speaking sample with psychedelic experience was not feasible. Results: The final, approved back‐translated versions of the MEQ‐4 and CEQ‐7 were developed, and the authorized Japanese versions of the MEQ‐4 and CEQ‐7 were established. Conclusions: In the present study, Japanese versions of the MEQ‐4 and CEQ‐7 were developed, enabling more rapid and efficient assessments of mystical and challenging experiences among Japanese speakers. Future studies should evaluate their comprehensibility, interpretability, cultural appropriateness, reliability, and validity in Japanese‐speaking samples.

  • Open Access

    A descriptive content analysis of greenwashing tactics used in US cigarette advertisements between 2019–2023

    by Maryam Ibrahim, Meghan B. Moran, Lauren Czaplicki, Ryan D. Kennedy, Dana Tfayli, Gideon P. Naudé, Justin C. Strickland, Matthew W. Johnson

    Introduction: The tobacco industry has incorporated strategies like greenwashing (i.e. a marketing tactic that utilizes false or unverified claims to mislead consumers about a business's environmental practices and impact) within cigarette advertisements. Despite regulation to limit...


  • Open Access

    Exploring self-reported health behavior change following naturalistic psychedelic use

    by Laura C. Carvalho, Jorge Encantado, Arlen C. Moller, Talea Cornelius, Natasza Marrouch, Matthew Johnson, Albert Garcia-Romeu, Diogo Veiga, Pedro J. Teixeira

    Health-related behaviors are essential determinants of health and well-being, yet unhealthy patterns persist globally. Psychedelics may represent an innovative tool for facilitating positive behavior change. This study investigated retrospective health-related behavior changes attributed to past psychedelic experiences. An online survey was completed by 271 adults who reported on the characteristics of their most impactful psychedelic experience and associated changes across 74 behaviors, including physical activity, and time spent in nature. The most frequently reported changes were in contemplative practices (63%), time spent in nature (55%), and personally meaningful social activities (54%). The majority of changes were reported in a healthy direction. Higher ratings of perceived meaningfulness and having a set intention emerged as significantly associated with overall healthy change. While causality cannot be inferred, these findings highlight the potential of psychedelic experiences as catalysts for health-related behavior change and underscore the role of intention and perceived meaningfulness as candidate mechanisms.


  • Open Access

    Time estimation variability in delay discounting: Model comparison and considerations

    by Brett W. Gelino, Madison E. Graham, Justin C. Strickland, Matthew W. Johnson, Derek D. Reed

  • Top Cited Papers

    Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions

    by Roland R. Griffiths, Robert Jesse, William A. Richards, Matthew W. Johnson, Nathan D. Sepeda, Anthony P. Bossis, Stephen Ross

    Background: Although historical writings, anthropological accounts, and experimental studies document associations between psilocybin use and religion, no prospective experimental study has investigated how the effects of psilocybin are experienced and interpreted by religious clergy. This exploratory study evaluated the overall safety and the acute and enduring effects of psilocybin in clergy. Methods: Participants were psychedelic-naïve clergy from various major world religions. A randomized, parallel group, waitlist control design was used to assess the effects of two supported psilocybin sessions, with participants receiving 20 and then 20 or 30 mg/70 kg about 1 month later. Outcomes were compared between the Immediate Group ( n = 13) and the Delayed Group ( n = 16) at 6 months after screening using self-report measures. The effects of psilocybin were also assessed on session days and 4 and 16 months after the second psilocybin session in the 24 participants who completed both sessions. Results: The primary outcome assessment at 6 months after screening showed that, compared with the delayed control group, participants who had received psilocybin reported significantly greater positive changes in their religious practices, attitudes about their religion, and effectiveness as a religious leader, as well as in their non-religious attitudes, moods, and behavior. Follow-up assessments showed that positive changes in religious and non-religious attitudes and behavior were sustained through 16 months after the second psilocybin session. At that time, participants rated at least one of their psilocybin experiences to be among the top five most spiritually significant (96%), profoundly sacred (92%), psychologically insightful (83%), and psychologically meaningful (79%) of their lives. Furthermore, 42% rated one of their experiences to be the single most profound of their lifetime. At 16-months follow-up, most (79%) strongly endorsed that the experiences had positive effects on their religious practices (e.g., prayer or meditation) and their daily sense of the sacred, and most (71%) reported positive changes in their appreciation of religious traditions other than their own. Although no serious adverse events were reported, 46% rated a psilocybin experience as among the top five most psychologically challenging of their lives. Conclusions: In this population of clergy, psilocybin administration was safe and increased multiple domains of overall psychological well-being including positive changes in religious attitudes and behavior as well as their vocation as a religious leader. The study was limited by a waitlist control design, homogenous sample, and the use of some unvalidated outcome measures. Further research with more rigorous control conditions and diverse samples is needed.


  • Open Access

    Adverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire

    by Kristoffer A.A. Andersen, Bjørn Holmøy, Tor-Morten Kvam, Matthew W. Johnson


  • Psychedelics and substance use disorder treatment

    by Caitlin M. DuPont, Matthew W. Johnson


  • A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research

    by David B. Yaden, Marianna Graziosi, Alexa M. Owen, Gabrielle Agin-Liebes, Scott T. Aaronson, Katja Ehrmann Allen, Frederick S. Barrett, Michael P. Bogenschutz, Robin Carhart-Harris, Terence H.W. Ching, et al.

    Introduction: Serotonergic psychedelics, serotonin 2A receptor agonists such as psilocybin that can result in substantially altered states of consciousness, are used in recreational and research settings. The safety of psychedelic experiences in research settings is supported by controlled physical environments, presence of clinical and medical staff to address emergent issues, screening for personal and family history of potential contraindications, and psychoeducational preparation with psychological support. Research settings typically provide psychoeducation to participants verbally and in writing (e.g., informed consent), and such documents and conversations can provide safety-related information—but may also introduce a wide range of expectancies. Such expectancies might involve the specific character of the acute subjective effects of psychedelics, possible side effects, and anticipated outcomes. Methods: To better understand the content of this psychoeducation, we gathered study materials from many psilocybin studies conducted in the past two decades in healthy and therapeutic populations. We conducted a reflexive thematic analysis to better understand these documents. Results: While these documents varied substantially between studies, we identified themes intended to lower levels of risk and optimize therapeutic effects from psychedelic treatments. The most frequently coded themes related to (1) biological and physical safety, (2) psychological safety and well-being, (3) aspects of setting, and (4) potential for expectancies. Prioritizing biological and psychological safety was evident in the materials from all sites. Furthermore, we identify potential contributors to expectancy unrelated to safety and suggest that these extrapharmacological elements be studied systematically in future research. Conclusions: : Ideally, future research should strive to maximize safety while attempting to minimize extraneous expectancies.


  • Experience with reduced‐nicotine cigarettes and whether this decreases smoking and substitution for full‐nicotine cigarettes

    by Gideon P. Naudé, Justin C. Strickland, Meredith S. Berry, Sean B. Dolan, David J. Cox, Matthew W. Johnson

    Studies suggest that reduced‐nicotine cigarettes decrease nicotine intake and dependence. However, questions remain about reduced‐nicotine cigarette abuse liability, whether reduced‐nicotine cigarette exposure lowers reduced‐ and full‐nicotine cigarette use, and whether reduced‐nicotine cigarettes substitute for full‐nicotine cigarettes. This randomized, double‐blind laboratory study used operant behavioral economics to examine abuse liability of cigarettes with varying nicotine content. Non‐treatment‐seeking smokers (N = 43) self‐administered reduced‐ (5.2, 2.4, or 1.3 mg/g) and full‐nicotine (15.8 mg/g) cigarettes before and after 3 weeks of at‐home exposure. Participants were randomized to full‐nicotine or one of the reduced‐nicotine cigarettes to determine the effect of exposure on abuse liability and substitutability. Abuse liability was assessed in single‐commodity sessions, and substitutability was measured in concurrent‐commodity sessions. In the self‐administration sessions, concurrently available reduced‐nicotine cigarettes attenuated full‐nicotine cigarette demand and rendered reduced‐nicotine cigarettes partial substitutes for full‐nicotine cigarettes. Exposure to study cigarettes for 3 weeks marginally reduced demand for reduced‐ and full‐nicotine cigarettes irrespective of nicotine content. Results suggest a limited influence of nicotine content on smoking behavior in established smokers and highlight the role of nonpharmacological factors (e.g., taste/smell) on the maintenance of smoking. These results should be considered in determining whether a nicotine‐reduction standard is a feasible path for reducing cigarette demand.